Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Common Equity: 2019-2025

Historic Common Equity for Beam Therapeutics (BEAM) over the last 7 years, with Sep 2025 value amounting to $966.0 million.

  • Beam Therapeutics' Common Equity rose 22.08% to $966.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $966.0 million, marking a year-over-year increase of 22.08%. This contributed to the annual value of $733.5 million for FY2024, which is 25.25% down from last year.
  • Latest data reveals that Beam Therapeutics reported Common Equity of $966.0 million as of Q3 2025, which was down 7.72% from $1.0 billion recorded in Q2 2025.
  • In the past 5 years, Beam Therapeutics' Common Equity registered a high of $1.1 billion during Q1 2025, and its lowest value of $422.4 million during Q1 2021.
  • For the 3-year period, Beam Therapeutics' Common Equity averaged around $887.4 million, with its median value being $854.1 million (2024).
  • Its Common Equity has fluctuated over the past 5 years, first skyrocketed by 326.76% in 2021, then declined by 25.25% in 2024.
  • Over the past 5 years, Beam Therapeutics' Common Equity (Quarterly) stood at $826.7 million in 2021, then decreased by 11.28% to $733.5 million in 2022, then skyrocketed by 33.79% to $981.3 million in 2023, then dropped by 25.25% to $733.5 million in 2024, then climbed by 22.08% to $966.0 million in 2025.
  • Its last three reported values are $966.0 million in Q3 2025, $1.0 billion for Q2 2025, and $1.1 billion during Q1 2025.